Cargando…

Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England

BACKGROUND: COVID-19 continues to pose a threat to public health. Booster vaccine programmes are critical to maintain population-level immunity. Stage theory models of health behaviour can help our understanding of vaccine decision-making in the context of perceived threats of COVID-19. PURPOSE: To...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Carly, Goffe, Louis, Antonopoulou, Vivi, Graham, Fiona, Tang, Mei Yee, Lecouturier, Jan, Grimani, Aikaterini, Chadwick, Paul, Sniehotta, Falko F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935297/
https://www.ncbi.nlm.nih.gov/pubmed/36933983
http://dx.doi.org/10.1016/j.vaccine.2023.02.047
_version_ 1784890015109611520
author Meyer, Carly
Goffe, Louis
Antonopoulou, Vivi
Graham, Fiona
Tang, Mei Yee
Lecouturier, Jan
Grimani, Aikaterini
Chadwick, Paul
Sniehotta, Falko F.
author_facet Meyer, Carly
Goffe, Louis
Antonopoulou, Vivi
Graham, Fiona
Tang, Mei Yee
Lecouturier, Jan
Grimani, Aikaterini
Chadwick, Paul
Sniehotta, Falko F.
author_sort Meyer, Carly
collection PubMed
description BACKGROUND: COVID-19 continues to pose a threat to public health. Booster vaccine programmes are critical to maintain population-level immunity. Stage theory models of health behaviour can help our understanding of vaccine decision-making in the context of perceived threats of COVID-19. PURPOSE: To use the Precaution Adoption Process Model (PAPM) to understand decision-making about the COVID-19 booster vaccine (CBV) in England. METHODS: An online, cross-sectional survey informed by the PAPM, the extended Theory of Planned Behaviour and Health Belief Model administered to people over the age of 50 residing in England, UK in October 2021. A multivariate, multinomial logistic regression model was used to examine associations with the different stages of CBV decision-making. RESULTS: Of the total 2,004 participants: 135 (6.7%) were unengaged with the CBV programme; 262 (13.1%) were undecided as to whether to have a CBV; 31 (1.5%) had decided not to have a CBV; 1,415 (70.6%) had decided to have a CBV; and 161 (8.0%) had already had their CBV. Being unengaged was positively associated with beliefs in their immune system to protect against COVID-19, being employed, and low household income; and negatively associated with CBV knowledge, a positive COVID-19 vaccine experience, subjective norms, anticipated regret of not having a CBV, and higher academic qualifications. Being undecided was positively associated with beliefs in their immune system and having previously received the Oxford/AstraZeneca (as opposed to Pfizer/BioNTech) vaccine; and negatively associated with CBV knowledge, positive attitudes regarding CBV, a positive COVID-19 vaccine experience, anticipated regret of not having a CBV, white British ethnicity, and living in East Midlands (vs London). CONCLUSIONS: Public health interventions promoting CBV may improve uptake through tailored messaging directed towards the specific decision stage relating to having a COVID-19 booster.
format Online
Article
Text
id pubmed-9935297
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Authors. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-99352972023-02-17 Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England Meyer, Carly Goffe, Louis Antonopoulou, Vivi Graham, Fiona Tang, Mei Yee Lecouturier, Jan Grimani, Aikaterini Chadwick, Paul Sniehotta, Falko F. Vaccine Article BACKGROUND: COVID-19 continues to pose a threat to public health. Booster vaccine programmes are critical to maintain population-level immunity. Stage theory models of health behaviour can help our understanding of vaccine decision-making in the context of perceived threats of COVID-19. PURPOSE: To use the Precaution Adoption Process Model (PAPM) to understand decision-making about the COVID-19 booster vaccine (CBV) in England. METHODS: An online, cross-sectional survey informed by the PAPM, the extended Theory of Planned Behaviour and Health Belief Model administered to people over the age of 50 residing in England, UK in October 2021. A multivariate, multinomial logistic regression model was used to examine associations with the different stages of CBV decision-making. RESULTS: Of the total 2,004 participants: 135 (6.7%) were unengaged with the CBV programme; 262 (13.1%) were undecided as to whether to have a CBV; 31 (1.5%) had decided not to have a CBV; 1,415 (70.6%) had decided to have a CBV; and 161 (8.0%) had already had their CBV. Being unengaged was positively associated with beliefs in their immune system to protect against COVID-19, being employed, and low household income; and negatively associated with CBV knowledge, a positive COVID-19 vaccine experience, subjective norms, anticipated regret of not having a CBV, and higher academic qualifications. Being undecided was positively associated with beliefs in their immune system and having previously received the Oxford/AstraZeneca (as opposed to Pfizer/BioNTech) vaccine; and negatively associated with CBV knowledge, positive attitudes regarding CBV, a positive COVID-19 vaccine experience, anticipated regret of not having a CBV, white British ethnicity, and living in East Midlands (vs London). CONCLUSIONS: Public health interventions promoting CBV may improve uptake through tailored messaging directed towards the specific decision stage relating to having a COVID-19 booster. The Authors. Published by Elsevier Ltd. 2023-04-06 2023-02-17 /pmc/articles/PMC9935297/ /pubmed/36933983 http://dx.doi.org/10.1016/j.vaccine.2023.02.047 Text en © 2023 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Meyer, Carly
Goffe, Louis
Antonopoulou, Vivi
Graham, Fiona
Tang, Mei Yee
Lecouturier, Jan
Grimani, Aikaterini
Chadwick, Paul
Sniehotta, Falko F.
Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England
title Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England
title_full Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England
title_fullStr Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England
title_full_unstemmed Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England
title_short Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England
title_sort using the precaution adoption process model to understand decision-making about the covid-19 booster vaccine in england
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935297/
https://www.ncbi.nlm.nih.gov/pubmed/36933983
http://dx.doi.org/10.1016/j.vaccine.2023.02.047
work_keys_str_mv AT meyercarly usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland
AT goffelouis usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland
AT antonopoulouvivi usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland
AT grahamfiona usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland
AT tangmeiyee usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland
AT lecouturierjan usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland
AT grimaniaikaterini usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland
AT chadwickpaul usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland
AT sniehottafalkof usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland